Novocure (NVCR) Stock Insights
NVCR$13.17-1.00 -7.06%
$1.53B
Market Cap
-11.29
P/E
6.93
Forward P/E
—
Score
NVCR price $13.17 -1.00 -7.06%
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 82888000 | 177026000 | 248069000 | 351318000 | 494366000 | 535031000 | 537840000 | 509338000 | 605220000 | 655353000 |
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain…
Insights · Dividends · Forecast · Financials · Learn
$1.53B
Market Cap
-11.29
P/E
6.93
Forward P/E
—
Score